Autopsy report · NCT00951132

Depression and Cardiovascular Risk Markers: Effects of Rosuvastatin Therapy

“Failure to include patients”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

University Hospital, Akershus

Sponsor type

University, hospital or other

Conditions

Depression

Interventions

rosuvastatin; Placebo

Participants

0

Sites

1

Countries

Norway

Trials that died the same way

• Endothelial Protection in Convalescent COVID-19 Patients
  “Lack of the eligible patients” (78% match in meaning)
• Serial Evaluation of Drug-Eluting Stents Using OCT (STRUT-OCT)
  “Lack of eligible patients” (78% match in meaning)
• Pyrexia Management Using an IL-6 Antibody in BRAF+ Melanoma Patients Treated with Dabrafenib/ Trametinib +/- Immunotherapy
  “too few patients could be included” (77% match in meaning)
• Epidermal Cells Delivery and Acute Burns
  “Not enough patients included” (77% match in meaning)
• RCVS: The Rational Approach to Diagnosis and Treatment
  “Failure to recruit patients meeting inclusion criteria.” (74% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.